4SEITZ AE,OLIVIER KN, STEINER CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States,1993 -2006[J]. Chest,2010,138(4) : 944- 949.
5KARADAG B, KARSKOC F, ERSU R, et al. Non-cysticfi- brosis bronchiectasis in children: a persisting problem in developing countries [ J ]. Respiration, 2005,72 ( 3 ) : 233 - 238.
6ARZU B, DUYUG O,NEVIN U,et al. A neglected problem of developing countries: noncystic fibrosis bronchiectasis [J]. Ann Thorac Med ,2009,4( 1 ) :21 -24.
7FLORESCU DF, MURPHY PJ, KALIL AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis [ J ]. Pulm Pharmacol Ther,2009,22 (6) : 467 - 472.
8WONG C, JAYARAM L, KARALUS N. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchi- ectasis ( EMBRACE ) : a randomised, double-blind, placebo- controlled trial [ J ]. Lancet, 2012,380 (9842) : 660 - 667.
9DE PF, POLUZZI E, MONTANARO N. QT-interval pro- longation by non-cardiac drugs:lessons to be learned from recent experience [ J ] . Eur J Clin Pharmacol, 2000,56 (1):1-18.
10RAY WA, MURRAY KT, HALL K. Azithromycin and the risk of cardio-vascular death [ J ]. N Engl J Med, 2012, 366(20) : 1881 - 1890.
